Jaguar Health issues 54k shares to Streeterville in exchange for Series Q preferred; adjourns annual meeting to June 2

Jaguar Health, Inc.

Issued 54,222 common shares to Streeterville in exchange for 7.96 shares of Series Q Preferred Stock.
Common shares to be issued without restrictive legend; Streeterville can resell under Rule 144 using tacked holding period from Aug 2022.
Annual Meeting adjourned to June 2, 2026; supplement to proxy to be filed after discussions with Nasdaq staff.
Company plans to provide additional information to stockholders regarding certain proposals in the proxy statement.
Record date remains April 15, 2026 for the reconvened meeting.

item 1.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-237195
form_type: 8-K
ticker: JAGX
cik: 0001585608
company_name: Jaguar Health, Inc.
filed_at: 2026-05-22T21:22:44+00:00
discovered_at: 2026-05-22T21:24:00.315816+00:00
generated_at: 2026-05-22T21:29:51.435816+00:00
sec_items: ["1.01", "8.01", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-237195
json_url: https://secwatch.observer/filing/0001193125-26-237195.json
markdown_url: https://secwatch.observer/filing/0001193125-26-237195.md
text_url: https://secwatch.observer/filing/0001193125-26-237195.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526237195/0001193125-26-237195-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526237195/d138181d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-237195

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.